The recognition is based on overall high performance in safety, quality and patient care.

Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ...

In 2025, we made significant strides towards advancing DrugSorb-ATR - a two-time U.S. Food and Drug Administration (FDA) Breakthrough Device - through the FDA De Novo submission process to reduce ...

It is a governance gap, and it has never been filled. Manitoba has commissioned expert reviews before. The Koshal report in 2003 created the cardiac sciences program and made 43 recommendations. Most ...

AdventHealth CEO brings cyclist mindset to navigate workforce, affordability, and tech challenges in healthcare delivery and ...

The entrepreneurial scene is evolving rapidly, with disruptive inventors transforming ideas into realities. From launchi ...

Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program ...

FDA review uncertainty, failed phase 3 for ersodetug in HI, high-risk upLIFT trial, tight cash runway—read more macro ...

Need a quote from a Motley Fool analyst? Cytosorbents is built around a differentiated blood purification platform designed ...

Q4 2025 Earnings Call March 25, 2026 4:30 PM EDTCompany ParticipantsPeter Mariani - Chief Financial OfficerPhillip Chan ...

Old internal affairs documents show Chris Nanos was suspended eight times for a total of 34 days as a member of the El Paso ...

Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript March 25, 2026 Cytosorbents Corporation misses on ...